Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
AIDS (London, England)|December 20, 2007
The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA studyColette J Smith, Christian H Olsen, Amanda Mocroft, et al.
AIDS (London, England)|February 19, 2005
Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimenChristian Holkmann Olsen, Jose Gatell, Bruno Ledergerber, et al.
HIV Clinical Trials|February 11, 2009
Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX studyAdrian Streinu-Cercel, Miguel de Gorgolas, Markus Müller, et al.
AIDS (London, England)|January 16, 2008
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDAWendy P Bannister, Lidia Ruiz, Alessandro Cozzi-Lepri, et al.
European Journal of Immunology|January 20, 2007
Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasmaMichael Humbert, Sascha Antoni, Boris Brill, et al.
Antiviral Therapy|June 27, 2007
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell countsAmanda Mocroft, Schlomo Staszewski, Rainer Weber, et al.
AIDS (London, England)|September 22, 2007
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitorsZoe V Fox, Anna Maria Geretti, Jesper Kjaer, et al.
AIDS (London, England)|December 20, 2003
An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistanceBrian G Gazzard, Anton L Pozniak, Willy Rosenbaum, et al.
The Journal of Infectious Diseases|October 2, 2002
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppressionAndrew N Phillips, Schlomo Staszewski, Fiona Lampe, et al.
AIDS (London, England)|June 27, 2008
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452)Brigitte Autran, Robert L Murphy, Dominique Costagliola, et al.
Pageof 7